Midostaurin Purification via Acidic Quenching and Silane Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preparing midostaurin fail to effectively reduce oxidation impurities below 0.1%, leading to purity and stability issues, and existing quenching procedures for the benzoylation reaction exacerbate these impurities, resulting in inefficiencies and high losses in the manufacturing process.
Innovation Solution
Treatment of crude midostaurin or staurosporine with strong organic or inorganic acids in a water-immiscible solvent, optionally with reducing silanes, and quenching the benzoylation reaction with an aqueous solution of slightly acid pH to limit the formation and increase of oxidation impurities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional quenching methods (water or bicarbonate solution) are used for the benzoylation reaction, then the reaction is terminated, but oxidation impurities significantly increase
Solution Approach 1:
The patent changes the pH parameter of the quenching solution from neutral (water) or basic (bicarbonate) to slightly acidic (pH 2-4), which prevents the formation of oxidation impurities while still terminating the benzoylation reaction effectively
Solution Approach 2:
The patent applies preliminary anti-action by using a slightly acidic quenching solution that preemptively prevents oxidation impurity formation before they can occur during the quenching process, rather than dealing with them after formation
2Manufacturing precision
If multiple crystallizations are performed to remove oxidation impurities, then purity increases, but yield losses and manufacturing inefficiency increase
Solution Approach 1:
The patent performs preliminary action by removing oxidation impurities during the quenching step itself, rather than requiring multiple subsequent crystallization steps. This single-step removal achieves high purity while maintaining manufacturing efficiency
Solution Approach 2:
The patent extracts oxidation impurities during the quenching process by forming water-soluble species that partition into the aqueous phase, allowing removal in a single operation rather than requiring multiple crystallization cycles
3Manufacturing precision
If methanesulfonic acid in alcohol is used for purification, then some impurities are removed, but toxic methanesulfonic esters are formed
Solution Approach 1:
The patent replaces the problematic methanesulfonic acid system with a simpler, safer acidic quenching solution (pH 2-4) that achieves purification without generating toxic byproducts, using a more benign chemical system
Solution Approach 2:
The patent converts the potentially harmful acidic conditions into a beneficial quenching mechanism where the slight acidity prevents oxidation impurity formation while the water-soluble nature of the quenching solution enables easy removal of impurities
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly decreases the content of 3-hydroxymidostaurin impurities in midostaurin to below 0.1%, enhancing the purity and stability of the drug while minimizing residual solvent content and maintaining manufacturing efficiency.
Implementation Method 1
treatment of crude midostaurin or staurosporine with strong organic or inorganic acids in a water-immiscible solvent, optionally with reducing silanes
Implementation Method 2
treatment of crude midostaurin or staurosporine with strong organic or inorganic acids in a water-immiscible solvent
Implementation Method 3
treatment of crude midostaurin or staurosporine with strong organic or inorganic acids in a water-immiscible solvent
Implementation Method 4
quenching the benzoylation reaction with an aqueous solution of slightly acid pH to limit the formation and increase of oxidation impurities
Data Source
AI summary
A process for the preparation of midostaurin with high purity, particularly a process for the preparation of midostaurin with a content of oxidation impurities lower than 0.1% comprising the treatment of crude midostaurin or staurosporine with strong organic or inorganic acids in a water-immiscible solvent and, optionally, also with reducing silanes is described.